Genetic Manipulation of Animal Cells & Transgenesis

Transgenics · Pronuclear Microinjection · ES Cell Chimeras · Retroviral Vectors

1. Genetic Manipulation of Animal Cells & Transgenesis

1.1 Fundamental Definitions & Terminology

Broadest Term
Genetically Modified Organism (GMO)
Any organism whose genetic material has been altered through any method, including conventional selective breeding, mutagenesis, or recombinant DNA technology.
Narrower Term
Genetically Engineered Organism
An organism whose genome has been specifically modified using recombinant DNA technology.
Most Specific
Transgenic Organism
A genetically engineered organism that stably integrates exogenous, foreign genetic material (a transgene) originating from a different species or synthetic source into its germline genome, passing it on to subsequent generations in a heritable manner.

Figure: The Genetic Manipulation Spectrum. Three nested categories of increasing specificity — every transgenic organism is genetically engineered, and every genetically engineered organism is a GMO, but the reverse is not true.

1.2 Historical Breakthroughs in Animal Transgenesis

The first transgenic mammals were engineered in 1981 by Ralph Brinster and Richard Palmiter. They introduced a chimeric gene fusion containing the coding region of the rat Growth Hormone (GH) gene driven downstream of the mouse Metallothionein-I (MT-I) inducible promoter into the fertilized eggs of mice. The resulting transgenic mice ("supermice") expressed high levels of rat GH upon zinc or heavy metal induction, growing to nearly twice the size of non-transgenic littermates.

1.3 Methods for Producing Transgenic Animals

Transgenesis requires the stable delivery of foreign DNA into a single totipotent or pluripotent cell capable of contributing to the complete development of an animal (including the germline). In mammals (primarily mice), three dominant methods are utilized:

Figure: Three Principal Routes to Transgenic Mice. Foreign DNA can be delivered by direct pronuclear microinjection of a zygote, by transfection of pluripotent ES cells followed by chimera formation, or by retroviral infection of an early cleavage-stage embryo.

Method 1: Pronuclear Microinjection

Step 1
Target Cell
Unfertilized oocytes are fertilized in vitro or harvested from superovulated females. Immediately post-fertilization, the male and female pronuclei remain distinct before syngamy.
Step 2
Injection Site
An aqueous solution containing linearized transgene DNA (free of vector backbone sequences) is microinjected directly into the male pronucleus using a fine glass capillary microneedle under an inverted microscope equipped with micromanipulators. The male pronucleus is chosen because it is significantly larger and positioned closer to the oocyte surface than the female pronucleus.
Step 3
Integration Mechanics
The microinjected DNA integrates randomly into the host chromosomal DNA, usually at a single genomic locus as tandem head-to-tail concatemers containing multiple copies (ranging from 1 to >100 copies). Integration relies on host non-homologous end joining (NHEJ) repair machinery.
Step 4
Implantation & Screen
Injected zygotes are transferred into the oviducts of pseudopregnant foster mothers (females mated with vasectomized males to induce necessary luteal hormonal support).
Outcome
Mosaicism vs. Germline Transmission
If integration occurs prior to the first cleavage division of the zygote, every somatic and germline cell in the resulting founder animal carries the transgene. If integration is delayed until after one or two cell divisions, the founder animal will be a mosaic (a mixture of transgenic and wild-type cells). If the transgenic cells contribute to the germline (testes/ovaries), breeding the founder with wild-type mice will produce fully transgenic F₁ offspring.

Figure: Pronuclear Microinjection. A holding pipette stabilizes the zygote while a fine glass microneedle delivers linearized transgene DNA directly into the larger, more accessible male pronucleus. Surviving zygotes are transferred to a pseudopregnant foster mother, and resulting founders are PCR-screened and bred to establish germline transmission.

Method 2: Transfection of Embryonic Stem (ES) Cells

Source
Source of ES Cells
ES cells are harvested from the inner cell mass (ICM) of 3.5-day pre-implantation blastocysts.
Property
Pluripotency & Culture
ES cells remain pluripotent in culture and can be expanded in vitro. When re-introduced into a recipient host blastocyst, ES cells integrate into the ICM and contribute to all tissue lineages of the developing embryo, including the germline.
Marker
Chimerism
Transfected ES cells (derived from a donor strain with a specific genetic marker, e.g., Agouti coat color A/A) are injected into blastocysts of a different host strain (e.g., Black coat color a/a). The resulting offspring are chimeras, visually identified by a patchwork agouti/black coat.
Screen
Germline Transmission Screening
Chimeric mice are bred with wild-type black mice (a/a). Agouti-colored offspring in the F₁ generation confirm that the ES cell genome successfully contributed to the functional germline gametes.

Figure: The ES Cell Chimera Pipeline. Genetically marked donor ES cells (Agouti A/A) are transfected, selected, and injected into a host blastocyst (Black a/a) to build a chimeric embryo. Chimeric offspring with a patchwork coat are bred with black mice; agouti-colored progeny confirm that the modified ES cells contributed to the functional germline.

Method 3: Retroviral Vector Method

Procedure
Infection Strategy
Replication-defective retroviruses are used to infect early-stage cleavage embryos (4- to 8-cell stages) in vitro.
Pros
Advantages
High efficiency of single-copy chromosomal integration without structural rearrangement.
Cons
Disadvantages
Strict physical constraint on the maximum transgene insert size (~8 kb), high rate of mosaicism, and potential risk of retroviral vector silencing or recombination.

Gene Knockout Technology & Homologous Recombination

Targeting Vectors · Positive-Negative Selection · Chimera Breeding · Mendelian Segregation

2. Gene Knockout Technology & Homologous Recombination

2.1 Distinction Between Genetic Alterations

Loss of Function
Gene Knockout
Complete permanent inactivation or deletion of an endogenous gene's functional coding sequence.
Targeted Addition
Gene Knock-in
Targeted insertion of a functional sequence, reporter gene (e.g., EGFP, LacZ), or specific point mutation into a precise endogenous chromosomal locus.
Reversible
Gene Knockdown
Temporary or partial reduction of mRNA/protein expression without altering the underlying genomic DNA sequence (e.g., via RNA interference or antisense oligonucleotides).

2.2 Molecular Architecture of a Targeting Vector

Gene knockout by homologous recombination requires a custom-built DNA targeting construct containing:

Component
Homology Arms
Two flanking genomic DNA regions (Left Arm and Right Arm, typically 2–5 kb each) identical in sequence to the targeted chromosomal locus.
Positive Marker
neo^r (Positive Selection)
The neomycin phosphotransferase gene (neo^r), which confers resistance to the cytotoxic drug G418 (Geneticin). The neo^r cassette is engineered inside the target gene coding region, simultaneously disrupting target gene function and providing positive selection.
Negative Marker
tk^HSV (Negative Selection)
The Herpes Simplex Virus Thymidine Kinase gene (tk^HSV), placed outside the flanking homology arms at the 3′ or 5′ terminus of the vector. The tk^HSV enzyme phosphorylates the nucleoside analog Ganciclovir, converting it into a lethal, cytotoxic tri-phosphate nucleoside that kills the cell.

Figure: Gene Targeting Vector Architecture. The construct places the neo^r positive-selection cassette between two genomic homology arms so it disrupts the target gene upon recombination, while the tk-HSV negative-selection marker sits outside the homology arms and is only retained after random, non-homologous integration.

2.3 Positive-Negative Selection (PNS) Scheme

When the targeting construct is transfected into cultured ES cells, three distinct genomic fates are possible:

Figure: The Positive-Negative Selection Scheme. Only cells that underwent homologous recombination gain the neo^r cassette without the flanking tk-HSV marker, so they alone survive both G418 and Ganciclovir — giving a targeted knockout ES cell clone. Random integration retains tk-HSV and is killed by Ganciclovir; cells with no integration are killed by G418.

Homologous Recombination (Targeted Integration)

Mechanism
Double-Crossover
Recombination occurs precisely between the vector's homology arms and the endogenous target gene. The endogenous target gene is replaced by the neo^r cassette, while the external tk^HSV marker is excluded and degraded.
Genotype
neo^r(+), tk^HSV(−)
Selection Outcome: SURVIVES G418 (due to neo^r) AND SURVIVES Ganciclovir (lacks tk^HSV).

Non-Homologous Recombination (Random Insertion)

Mechanism
NHEJ Integration
The entire targeting vector integrates randomly into non-homologous chromosomal breaks via NHEJ. Both the internal neo^r cassette AND the terminal tk^HSV gene are integrated into the genome.
Genotype
neo^r(+), tk^HSV(+)
Selection Outcome: SURVIVES G418 BUT IS KILLED BY GANCICLOVIR (because tk^HSV metabolizes Ganciclovir into a toxin).

No Integration

Mechanism
Vector Degraded
The vector fails to integrate and is degraded.
Genotype
neo^r(−), tk^HSV(−)
Selection Outcome: KILLED BY G418.

2.4 Breeding Pipeline for Homozygous Knockout Mice

Step 1
ES Cell Selection
Targeted ES cell clones (neo^r+, tk^HSV−) are verified by PCR or Southern blot.
Step 2
Blastocyst Microinjection
Selected ES cells (+/− for target gene) are microinjected into host blastocysts and implanted into pseudopregnant foster mothers.
Step 3
Chimeric Offspring
Offspring showing coat-color chimerism are selected.
Step 4
Germline Breeding
Chimeras are bred with wild-type mice to yield F₁ heterozygous knockout mice (+/−).
Step 5
Intercrossing
Heterozygotes (+/−) are intercrossed (+/− × +/−). According to Mendelian inheritance, 25% of the F₂ progeny will be homozygous knockout mice (−/−), completely lacking functional target protein.

Figure: Breeding Pipeline for Homozygous Knockout Mice. Verified targeted ES cell clones are injected into blastocysts to produce chimeras, which are bred to wild-type mice for germline transmission of the F₁ heterozygotes. Intercrossing heterozygotes yields the classic 1:2:1 Mendelian ratio in F₂, with 25% of progeny homozygous knockouts entirely lacking the target gene product.

Nuclear Transfer Technology, SCNT & Reproductive Cloning

Nuclear Transfer Technology & Reproductive Cloning

Somatic Cell Nuclear Transfer · Dolly the Sheep · Reproductive vs. Therapeutic Cloning

3. Nuclear Transfer Technology, Somatic Cell Nuclear Transfer (SCNT) & Reproductive Cloning

3.1 Historical Milestones in Animal Cloning

1952
Briggs & King
First successful nuclear transfer in amphibians using blastula embryonic nuclei in Rana pipiens.
1962
John Gurdon
Demonstrated totipotency of differentiated intestinal epithelial cell nuclei in Xenopus laevis (awarded the 2012 Nobel Prize).
1995
Ian Wilmut & Keith Campbell
Produced live lambs (Megan and Morag) via nuclear transfer from cultured embryonic cell lines.
1997
Wilmut & Campbell — Roslin Institute
Created Dolly the Sheep, the first mammal cloned from an adult somatic cell (mammary gland epithelial cell of a 6-year-old Finn Dorset ewe).

Figure: Historical Milestones in Animal Cloning. From Briggs and King's first amphibian nuclear transfer through Gurdon's proof of nuclear totipotency to Wilmut and Campbell's cultured-cell lambs, each milestone built toward Dolly the Sheep in 1997 — the first mammal cloned from a fully differentiated adult somatic cell.

3.2 Somatic Cell Nuclear Transfer (SCNT) Protocol

Figure: The SCNT Pipeline. A quiescent adult somatic cell nucleus is delivered into an enucleated oocyte cytoplast by electrofusion, which simultaneously triggers artificial activation. The reconstructed zygote is cultured to the blastocyst stage and transferred to a surrogate mother, yielding offspring genetically identical to the somatic cell donor.

Donor Cell Quiescence (G₀ Phase Induction)

Step 1
Serum Starvation
Cultured adult donor somatic cells are subjected to serum starvation (0.5% fetal bovine serum), forcing the cells to exit the active cell cycle and enter a quiescent G₀ phase.
Why It Matters
Chromatin Synchrony
G₀ cell cycle arrest is critical to synchronize the chromatin state, making the donor DNA responsive to oocyte cytoplasmic reprogramming factors and preventing DNA replication anomalies after fusion.

Recipient Oocyte Enucleation

Step 2
Oocyte Harvest
Unfertilized oocytes are harvested and held at Metaphase II (MII) of meiosis.
Technique
Chromosome Aspiration
Using a micromanipulator, the polar body and adjacent metaphase chromosome plate are aspirated with a micropipette, generating an enucleated oocyte cytoplast.

Electrofusion & Artificial Activation

Step 3
Cell Placement
A quiescent donor somatic cell is placed into the perivitelline space of the enucleated oocyte.
Fusion
DC Electric Pulse
A short pulse of high-voltage direct current (DC) is applied (electrofusion). This destabilizes plasma membranes, causing the somatic cell and oocyte to fuse, delivering the somatic nucleus into the cytoplasm.
Activation
Calcium Oscillations
The electric pulse also induces artificial oocyte activation by triggering intracellular calcium oscillations, initiating embryonic development without fertilization.

Embryonic Development & Transfer

Step 4
In Vitro Culture
Reconstructed embryos are cultured in vitro to the morula/blastocyst stage.
Step 5
Surgical Transfer
Intact blastocysts are surgically transferred into the uterus of a synchronized surrogate mother.

3.3 Reproductive vs. Therapeutic Cloning

Live Organism
Reproductive Cloning
Goal is the birth of a complete, live-born cloned organism genetically identical to the somatic cell donor.
Cell Therapy
Therapeutic Cloning
Goal is to culture reconstructed blastocysts in vitro to derive patient-specific embryonic stem cells (ntESCs) from the inner cell mass for cell replacement therapy and tissue engineering, without implanting the embryo into a surrogate.

Figure: Reproductive vs. Therapeutic Cloning. Both paths begin from the same reconstructed blastocyst produced by SCNT. Reproductive cloning implants the embryo into a surrogate to birth a live, genetically identical clone, while therapeutic cloning stops at the blastocyst stage in vitro, harvesting the inner cell mass to derive patient-matched ntESCs for regenerative therapies.

Human Gene Therapy Protocols & Vector Systems

Somatic & Germline Therapy · In Vivo / Ex Vivo Delivery · Retroviral, Adenoviral & AAV Vectors

4. Human Gene Therapy Protocols & Vector Systems

4.1 Fundamentals & Definitions

Gene therapy is the introduction, alteration, or suppression of specific genetic material within human somatic or germline cells to treat, prevent, or cure a disease.

Standard Approach
Gene Addition (Augmentation)
Inserting a functional gene copy into a non-specific locus to compensate for a non-functional mutant allele.
Targeted Swap
Gene Replacement
Homologous recombination to directly replace a mutant allele with a wild-type functional copy.
Precision Fix
Gene Repair
Targeted correction of a specific point mutation (e.g., using CRISPR/Cas9 prime editing).

4.2 Classifications of Gene Therapy

Non-Heritable
Somatic Cell Gene Therapy
Transgene is introduced exclusively into non-germline somatic cells (e.g., bone marrow, liver, lung epithelium). Genetic alterations are restricted to the patient and are not heritable.
Banned Worldwide
Germline Gene Therapy
Transgene is introduced into gametes, zygotes, or early embryos. Genetic modifications are permanently integrated into all cells (including germ cells) and are heritably transmitted to offspring. Currently banned in humans worldwide due to ethical and safety concerns.

4.3 Historical Landmark: Ashanti DeSilva (1990)

The first approved human gene therapy trial was performed in September 1990 by W. French Anderson, R. Michael Blaese, and Kenneth Culver.

Patient
4-Year-Old Ashanti DeSilva
Suffering from Severe Combined Immunodeficiency (SCID) caused by an inherited deficiency in Adenosine Deaminase (ADA).
Protocol
Ex Vivo T-Cell Correction
Autologous T-lymphocytes were isolated from her blood, transduced ex vivo with a retroviral vector encoding functional human ADA cDNA, expanded in culture, and re-infused into her bloodstream.

4.4 Major Human Disease Targets for Somatic Gene Therapy

Disease Target	Affected Cell / Tissue Target	Therapeutic Transgene(s)
ADA-SCID	Bone marrow hematopoietic stem cells / T-cells	Adenosine Deaminase (ADA)
Hemophilia A	Liver hepatocytes, endothelial cells	Coagulation Factor VIII (F8)
Hemophilia B	Liver hepatocytes	Coagulation Factor IX (F9)
Cystic Fibrosis	Airway epithelial cells	CF Transmembrane Conductance Regulator (CFTR)
Familial Hypercholesterolemia	Liver hepatocytes	Low-Density Lipoprotein Receptor (LDLR)
Gaucher's Disease	Macrophages / Bone marrow stem cells	Glucocerebrosidase (GBA)
Cancer	Tumor cells / Cytotoxic T-lymphocytes	p53, Rb, CAR-T constructs, Interleukins

4.5 Delivery Strategies: In Vivo vs. Ex Vivo

Direct Delivery
In Vivo Gene Therapy
Therapeutic vectors are administered directly into the patient's body (systemically via intravenous infusion or locally via targeted tissue injection, e.g., subretinal injection for retinal dystrophy).
Autologous
Ex Vivo Gene Therapy
Target cells are harvested from the patient via biopsy (e.g., bone marrow stem cells), cultured in vitro, transduced with the therapeutic gene vector, selected/expanded, and transplanted back into the patient (autologous transplantation). Eliminates immune rejection risks.

Figure: In Vivo vs. Ex Vivo Gene Therapy. In vivo delivery injects the vector directly into the target tissue, transducing cells in place. Ex vivo delivery isolates patient cells first, transduces and expands them outside the body, then re-infuses the corrected, autologous cells — avoiding immune rejection risk entirely.

4.6 Non-Viral Delivery Systems

Mechanism
Liposome-Mediated Transfection (Lipoplexes)
Synthetic cationic lipids mix with negatively charged plasmid DNA to form lipoplexes. The lipid envelope fuses with host cell membranes or undergoes endocytosis.
Advantages
Lipoplex Benefits
Non-pathogenic, low immunogenicity, unlimited DNA insert capacity.
Disadvantages
Lipoplex Limitations
Low transfection efficiency, transient expression, lack of genomic integration.
Mechanism
Biolistics (Gene Gun)
Heavy metal microparticles (gold or tungsten) coated with DNA are accelerated by high-pressure helium gas into target tissue (e.g., skin or muscle).

4.7 Viral Vector Delivery Systems

Figure: Viral Vector Systems at a Glance. Retroviruses integrate but only infect dividing cells; adenoviruses infect broadly but stay episomal and transient; AAV combines broad infectivity with long-term, largely non-integrating persistence.

1. Retroviral Vectors (Moloney Murine Leukemia Virus — MMLV)

Genome
ssRNA (~8 kb)
Converts to dsDNA via reverse transcriptase and integrates into the host chromosome using integrase.
Target Cells
Dividing Cells Only
Exclusively infects actively dividing cells (nuclear envelope breakdown required for pre-integration complex entry).

Safety Engineering (Packaging Cell System)

Wild Type
Structural Genes
Wild-type MMLV genome contains structural genes gag (capsid), pol (reverse transcriptase/integrase), env (envelope), flanked by Long Terminal Repeats (LTRs) and a ψ (psi) packaging signal.
Vector Design
Replication-Defective
To make the vector replication-defective, gag, pol, and env are deleted from the vector and replaced by the therapeutic expression cassette. The ψ packaging signal is retained.
Helper Cells
Packaging Cell Line
Engineered host cells stably express gag, pol, and env from a helper plasmid lacking the ψ signal.
Outcome
Single-Cycle Virion
When the therapeutic vector (containing ψ) is transfected into packaging cells, the viral proteins package the therapeutic RNA into viral particles. The released virions can infect target host cells and integrate the therapeutic gene, but cannot replicate because they lack gag/pol/env.

Figure: The Retroviral Packaging Cell System. The therapeutic vector keeps only the ψ packaging signal and LTRs around the transgene; the helper genome supplies gag/pol/env but lacks ψ, so only the therapeutic RNA gets packaged into virions — producing particles that can transduce a target cell exactly once and cannot replicate further.

2. Adenoviral Vectors

Genome
Linear dsDNA (~36 kb)
Non-enveloped, linear double-stranded DNA.
Integration
Non-Integrating (Episomal)
Does not integrate into host chromosomal DNA, remaining as an episome in the nucleus.
Target Cells
Dividing & Non-Dividing
Efficiently infects both dividing and non-dividing cells.
Key Advantage
High Capacity & Efficiency
High capacity (>30 kb) and high transduction efficiency.
Key Disadvantage
Immunogenic & Transient
High immunogenicity (induces strong inflammatory response) and transient expression (lost during host cell division).

3. Adeno-Associated Virus (AAV) Vectors

Genome
ssDNA (~4.7 kb)
Non-enveloped, single-stranded DNA.
Integration
Site-Specific / Episomal
Wild-type AAV integrates site-specifically into human Chromosome 19 (AAVS1 locus). Recombinant viral vectors mostly persist as long-term stable episomes.
Target Cells
Dividing & Non-Dividing
Infects both dividing and non-dividing cells.
Key Advantage
Low Immunogenicity, Long-Term
Extremely low immunogenicity, non-pathogenic, provides long-term expression in post-mitotic tissues (e.g., neurons, cardiac muscle, retina).
Key Disadvantage
Small Packaging Capacity
Small packaging capacity (≤ 4.5 kb).

Transgenic Plant Biotechnology & Agrobacterium-Mediated Transformation

Transgenic Plant Biotechnology

Agrobacterium-Mediated Transformation · Ti Plasmid · Bt Crops, Golden Rice & Flavr Savr

5. Transgenic Plant Biotechnology & Agrobacterium-Mediated Transformation

5.1 The Agrobacterium tumefaciens System

Agrobacterium tumefaciens is a soil phytopathogenic bacterium that naturally infects dicotyledonous plants at wound sites, causing crown gall disease (tumor growth).

~200 kb
Ti Plasmid
The Tumor-Inducing Plasmid carries the T-DNA and the virulence region that together drive plant transformation.
Transferred DNA
T-DNA
Flanked by 25-bp direct border repeats (Left Border [LB] and Right Border [RB]). T-DNA contains genes encoding oncogenes (auxin and cytokinin biosynthesis genes causing cell proliferation) and opines (octopine or nopaline synthesis genes used by the bacterium as carbon/nitrogen sources).
vir Genes
Virulence (vir) Region
Encodes Vir proteins (VirA through VirG) that mediate T-DNA excision, processing, export, and nuclear targeting.

Figure: Ti Plasmid Architecture. Only the T-DNA segment — bounded by the LB and RB repeats — is excised and transferred into the plant cell; the oncogenes drive gall formation and the opine genes feed the bacterium, while the vir region and oriV remain in the bacterium and are never transferred.

5.2 Disarmed Vector Systems & Plant Selectable Markers

To make Ti plasmids useful vectors, they are disarmed by removing the oncogenes (auxin/cytokinin) and opine genes from between the 25-bp borders, replacing them with multiple cloning sites (MCS) and selectable marker cassettes.

Selectable Marker Gene	Enzyme Encoded	Selective Agent (Antibiotic/Herbicide)
NPTII	Neomycin phosphotransferase II	Kanamycin / G418
HPT / HYG	Hygromycin phosphotransferase	Hygromycin B
BAR / PAT	Phosphinothricin acetyltransferase	Glufosinate / Phosphinothricin (Basta)
EPSPS (AroA)	5-Enolpyruvylshikimate-3-phosphate synthase	Glyphosate (Roundup)
BXN	Nitrilase	Bromoxynil
ALS	Acetolactate synthase	Chlorsulfuron

5.3 Major Agronomic Applications of Transgenic Plants

Figure: Major Agronomic Applications of Transgenic Plants. Five commercialized applications of plant biotechnology span pest control, weed management, disease resistance, nutrition, and post-harvest quality.

Insect Resistance (Bt Crops)

Transgene
Cry δ-Endotoxins
Transgenes encoding δ-endotoxins (Cry proteins) from Bacillus thuringiensis are expressed in crops (e.g., Bt cotton, Bt corn).
Mechanism
Midgut Pore Formation
Insects ingest crystalline Cry protoxins. In the alkaline environment of the insect midgut, host proteases cleave the protoxin into active toxic fragments. The active toxin binds specific cadherin receptors on midgut epithelial cells, forming pores that disrupt osmotic balance, causing cell lysis and insect death.

Herbicide Resistance (Glyphosate / Roundup Ready)

Target
Shikimate Pathway
Glyphosate inhibits EPSP synthase, a key enzyme in the shikimate pathway required for synthesizing aromatic amino acids (phenylalanine, tyrosine, tryptophan).
Engineering
Insensitive EPSPS
Transgenic crops express an insensitive mutant EPSP synthase gene (AroA from Agrobacterium sp. strain CP4) or overexpress wild-type EPSP synthase.

Nutritional Improvement (Golden Rice)

Inventors
Potrykus & Beyer
Engineered by Ingo Potrykus and Peter Beyer to synthesize β-carotene (pro-vitamin A) in rice endosperm.
Pathway
Two-Gene Reconstruction
Introduced two key genes: Phytoene synthase (psy from daffodil Narcissus pseudonarcissus) and Phytoene desaturase (crtI from bacterium Erwinia uredovora).

Delayed Fruit Ripening (Flavr Savr Tomato)

Developer
Calgene
Engineered by Calgene using antisense technology.
Mechanism
Antisense PG Blockade
An antisense gene complementary to polygalacturonase (PG) mRNA is expressed. Polygalacturonase degrades pectin in fruit cell walls during ripening. Antisense RNA pairs with endogenous PG mRNA, blocking translation and activating degradation, delaying fruit softening and extending shelf-life.

Post-Transcriptional Gene Silencing, Antisense Technology & RNA Interference

Post-Transcriptional Gene Silencing & RNA Interference

Antisense Oligonucleotides · Ribozymes · siRNA & the RISC-Argonaute Pathway

6. Post-Transcriptional Gene Silencing (PTGS), Antisense Technology, & RNA Interference

Figure: Three Routes to Post-Transcriptional Gene Silencing. Antisense oligonucleotides and ribozymes act as single designed molecules that block or cleave a target transcript directly, while RNA interference uses the cell's own Dicer/RISC machinery to process long dsRNA into guide-strand siRNAs that direct sequence-specific mRNA slicing.

6.1 Single-Stranded Antisense Oligonucleotides

Short synthetic single-stranded DNA/RNA sequences (15–20 nucleotides) complementary to target mRNA.

Mechanism
Steric Blockade
Binds to the 5′ cap or AUG initiation codon, physically preventing ribosome assembly and scanning.
Mechanism
RNase H Activation
Forms an RNA-DNA heteroduplex, serving as a substrate for endogenous RNase H, which specifically cleaves the mRNA strand.

6.2 Ribozymes

Catalytic RNA
Hammerhead Ribozyme
Catalytic RNA molecules engineered with sequence-specific substrate-binding arms flanking a catalytic core.
Mechanism
Site-Specific Cleavage
Binds target mRNA via complementary base pairing and site-specifically cleaves phosphodiester bonds adjacent to 5′-UH-3′ motifs (where H = A, C, or U).

6.3 RNA Interference (RNAi)

Discovered by Andrew Fire and Craig Mello in 1998 in Caenorhabditis elegans (2006 Nobel Prize).

Step 1
Dicer Processing
Long double-stranded RNA (dsRNA) is recognized and cleaved in the cytoplasm by the RNase III-family enzyme Dicer into 21–23 bp small interfering RNAs (siRNAs) with 2-nt 3′ overhangs.
Step 2
RISC Loading
siRNA duplexes are loaded into the RNA-Induced Silencing Complex (RISC).
Step 3
Strand Selection
The passenger strand is degraded, while the guide strand guides RISC to complementary target mRNA.
Step 4
Argonaute Slicing
The catalytic Argonaute core (Ago2) slices the target mRNA, causing complete transcript degradation and gene silencing.

Figure: The RNAi Mechanism. Dicer processes long dsRNA into siRNA duplexes, which load into RISC. After the passenger strand is discarded, the guide strand directs RISC to a complementary mRNA, where the Argonaute (Ago2) slicer catalytic core cleaves the transcript, silencing the gene.

Solved Advanced Analytical & Quantitative Problems

Gene Targeting Efficiency · PNS Selection Math · SCNT Cloning Efficiency

7. Solved Advanced Analytical & Quantitative Problems

Problem 1: Gene Targeting & PNS Selection Analysis in ES Cells

A knockout construct targeting the mouse p53 gene is electroporated into 10⁷ cultured ES cells. The vector contains a neo^r insertion in exon 2 of p53 and a terminal tk^HSV gene.

Given

Total electroporated cells plated: 10⁷
Plated on G418 alone: yields 5,000 surviving colonies
Plated on G418 + Ganciclovir (PNS double selection): yields 50 surviving colonies

Calculate

The absolute frequency of overall transfection/integration.
The proportion of stable integration events resulting from homologous recombination versus random insertion.
The enrichment factor provided by negative selection with Ganciclovir.

Solution

1. Transfection / Integration Frequency

Cells surviving G418 alone have integrated the vector (either homologously or randomly).

Integration Frequency = 5,000 G418-resistant colonies10⁷ total electroporated cells = 5 × 10⁻⁴

= 0.05%

2. Targeting Efficiency (Homologous Recombination Proportion)

Colonies surviving BOTH G418 and Ganciclovir represent true targeted homologous recombination events (neo^r+, tk^HSV−). Number of targeted knockout colonies = 50. Total stable integrants = 5,000.

Proportion of Homologous Recombination = 505,000 = 0.01

= 1.0%

Random non-homologous insertion accounts for 99.0% (4,950 colonies) of integration events.

3. Enrichment Factor

Enrichment Factor = Colonies surviving G418 aloneColonies surviving G418 + Ganciclovir = 5,00050

= 100-fold

Negative selection with Ganciclovir eliminated 99% of non-targeted background, enriching for targeted knockouts by 100-fold.

Problem 2: SCNT Cloning Efficiency & Cell Cycle Synchronization

In an SCNT animal cloning experiment:

Given

Total unfertilized oocytes enucleated: 500
Donor somatic cells fused and activated successfully: 400 reconstructed zygotes
Reconstructed zygotes developing into blastocysts in vitro: 80
Blastocysts implanted into surrogate mothers yielding live births: 2 live clones

Calculate

The blastocyst development rate (based on reconstructed zygotes).
The overall cloning efficiency per reconstructed zygote.

Solution

1. Blastocyst Development Rate

Blastocyst Rate = 80 blastocysts400 reconstructed zygotes × 100

= 20.0%

2. Overall SCNT Cloning Efficiency

Overall Cloning Efficiency = 2 live births400 reconstructed zygotes × 100

= 0.5%

Note: Typical SCNT cloning efficiencies in mammals range between 0.5% and 3.0%, reflecting epigenetic reprogramming barriers.

In this lesson

LessonStep 29 of 33

Next quizTransgenic Animals, Gene Targeting, and Gene Therapy